Skip to main content
Download PDF

The anti-inflammatory properties of vinpocetine mediates its therapeutic potential in management of atherosclerosis

Journal of Inflammation volume 21, Article number: 19 (2024) Cite this article

Abstract

Atherosclerosis (AS) formation is enhanced by different mechanisms including cytokine generation, vascular smooth muscle cell proliferation, and migration. One of the recent treatments towards endothelial dysfunction and AS is Vinpocetine (VPN). VPN is a potent inhibitor of phosphodiesterase enzyme 1 (PDE-1) and has anti-inflammatory and antioxidant effects through inhibition the expression of nuclear factor kappa B (NF-κB). VPN has been shown to be effective against the development and progression of AS. However, the underlying molecular mechanism was not fully clarified. Consequently, objective of the present review was to discuss the mechanistic role of VPN in the pathogenesis AS. Most of pro-inflammatory cytokines that released from macrophages are inhibited by action of VPN through NF-κB-dependent mechanism. VPN blocks monocyte adhesion and migration by constraining the expression and action of pro-inflammatory cytokines. As well, VPN is effective in reducing of oxidative stress a cornerstone in the pathogenesis of AS through inhibition of NF-κB and PDE1. VPN promotes plaque stability and prevents the erosion and rupture of atherosclerotic plaque. In conclusion, VPN through mitigation of inflammatory and oxidative stress, and improvement of plaque stability effects could be effective agent in the management of AS.

Introduction

Vinpocetine (VPN) is an ethyl apovincaminate derived from vinca alkaloid vincamine (Fig. 1) which extracted from Vocanga Africana seeds and Vinca minor leaves [1].

Fig. 1
figure 1

Semisynthesis of vinpocetine from natural alkaloid vincamine

Full size image

VPN was discovered in 1978 in Hungary, and have been extensively used in different cerebrovascular disorders [2]. VPN was used in the management of dementia and stroke in European and Asian countries, though it was not approved for therapeutic use in USA [3]. Despite of the extensive use of VPN as nootropic and dietary supplement, it was not approved by FDA. VPN was first used in 1978 in treating of dementia, stroke, and memory disorders [4].

The mechanism of VPN is related to inhibition of sodium channel, reduction of calcium influx and antioxidant effects [5]. VPN is regarded as potent inhibitor of phosphodiesterase enzyme 1 (PDE-1). VPN has an anti-inflammatory effect by inhibiting the expression of nuclear factor kappa B (NF-κB) through stabilization of IκB which is an inhibitor of NF-κB. Moreover, VPN have anti-platelet activity, thereby; improves brain blood flow and brain metabolism [6].

Currently, VPN is also available in the market as a dietary supplement to enhance cognition and memory. Due to its excellent safety profile, increasing efforts have been put into exploring the novel therapeutic effects and mechanism of actions of VPN in various cell types and disease models. Recent studies have revealed a number of novel functions of VPN, including anti-inflammation, antagonizing injury-induced vascular remodeling, and high-fat-diet-induced atherosclerosis (AS) as well as attenuating pathological cardiac remodeling. These novel findings may simplify the repositioning of VPN for preventing or treating relevant disorders in humans [7].

Prolonged use of VPN is associated with the development of certain adverse effects including hypotension, tachycardia, dizziness, dry mouth, nausea, heartburn and flushing [8]. To date, there have been no reports of significant side effects, toxicity, or contraindications at therapeutic doses of VPN on the cardiovascular system; therefore it is an interesting compound to explore novel therapeutic applications. A recent study shown a cardioprotective effect of VPN in a rat myocardial infarction model induced by acute treatment with isoproterenol. Isoproterenol-induced cardiomyopathy in rat is reflected by increased serum markers of myocardial infarction such as serum creatine kinase-MB, lactate dehydrogenase, glutamic oxaloacetic transaminase, and Troponin-T, as well as histopathological features of myocardial infarction such as myocardial necrosis, edema, infiltration of macrophages and lymphocytes. The cardiac damage induced by isoproterenol seemed to involve reactive oxygen species (ROS) and VPN treatment increased the activity of a number of antioxidant enzymes [9]. It has been shown that chronic Angiotensin II infusion induced cardiac hypertrophy and cardiac fibrosis is noticeably reduced by systemic administration of VPN. Furthermore, in isolated adult mouse cardiomyocytes, VPN inhibited Angiotensin II-stimulated cardiomyocytes hypertrophic growth. In cultured cardiac fibroblasts, VPN inhibits fibroblast activation and matrix gene expression, such as smooth muscle alpha-actin, type I collagen and fibronectin [10].

VPN has a specific pharmacokinetic profile; the effective therapeutic dosage of VPN is 5–10 mg [11]. VPN half-life is 1–2 h; it highly absorbed from intestine with 56.6% bioavailability, peak plasma level is reached after one hr of oral administration, highly distributed, cross blood brain barrier (BBB), metabolized by liver and excreted by urine [12]. It has been reported that VPN was effective against the development and progression of atherosclerosis (AS) [7]. Though, the underlying molecular mechanism was not fully clarified. Consequently, objective of the present narrative review was to clarify the mechanistic role of VPN in AS.

Atherosclerosis overview

AS is a vascular disease characterized by thickening of the intimal layer of arteries and accumulation of fat. Fatty material is located in the central core of the plaque, covered by fibrous cap. The term, atherosclerosis consists of two parts; atherosis (accumulation of fat accompanied by several macrophages) and sclerosis (fibrosis layer comprising smooth muscle cells [SMC], leukocyte, and connective tissue) [13]. AS is an advanced disease impedes blood flow causing tissue ischemia predominantly in the brain and heart [14]. AS complications such as peripheral vascular disease, stroke and myocardial infarction are the major causes of mortality. AS process may be started in childhood but demonstrated clinically in the middle age and later [15]. Rupture of atherosclerotic plaques and associated thromboembolic disorders are the main reason for cardiovascular complications [16]. The underlying associated pathological conditions connected with AS progression are inflammation, oxidative stress, endothelial dysfunction, apoptosis, vascular proliferation, matrix degeneration, and neovascularization [17].

Hypercholesterolemia is considered as the chief inducer of AS, as increasing of circulating cholesterol increase the endothelial permeability and deposition of lipid particles in the vascular endothelium [18, 19]. Lipid particles primarily LDL in the sub-endothelial space act as chemo-attractants for the monocytes which converted to foamy macrophages. Furthermore, oxidized LDL in the sub-endothelial space activates the expression of scavenger receptors on the macrophages with additional buildup of intracellular cholesterol. These pathological changes encourage plaque formation, narrowing of vascular lumen and development of AS [20]. Atherosclerotic plaques are vulnerable for erosion, rupture, and calcification with nodule formation, and higher infiltration of T cells into atherosclerotic plaque increases vulnerability for rupture and thrombosis [21].

High LDL and TG with low HDL act as strong predictors for the development of premature AS [22]. However, high HDL level is considered as a protective factor against development and progression of AS [23]. Moreover, hypertriglyceridemia is regarded as independent risk factor for progression of AS [24]. Similarly, lipoprotein disorders are associated with AS pathophysiology, increased lipoprotein A is related with AS development [25].

Particularly, macrophage is the most immune cell intricate with progression of AS and atherosclerotic complications including erosion and rupture, typically, immune cells mostly macrophages consume oxidized LDL (ox-LDL) with production of ROS [26]. In order, excessive production of ROS promotes development of oxidative stress and progression of plague instability [27]. Consequently, ox-LDL accelerates macrophage oxidative stress process with progression of oxidative stress.

Oxidative stress together with inflammation enhance AS progression in a vicious cycle as inflammation induces oxidative stress and vice versa. Oxidative stress stimulates the expression of inflammatory signaling pathway, pro-inflammatory cytokines, and chemokines which in turn enhance ROS generation [28]. NADPH-oxidase is extensively expressing enzyme primarily vascular smooth muscle involved in ROS generation, higher expression of NADPH-oxidase is increased by aging process leading to endothelial dysfunction, vascular inflammation, and mitochondrial and cellular-induced oxidative stress [29].

It has been revealed that ox-LDL activates infiltration of monocytes and migration of smooth muscle cells, it contributes to atherothrombosis through induction apoptosis of endothelial cells, plaque erosion, production of tissue factors, and impairment of endogenous anticoagulant pathway [30]. HDL attenuates the production and effect of ox-LDL, though; oxidized HDL (ox-HDL) loss the vasculoprotective effect and act as pro-inflammatory and proartherogenic mediator and increase risk of AS progression [31]. Remarkably, ox-HDL promotes the progression of atherosclerotic plaque erosion and rupture. Hence, ox-HDL is regarded as a potential risk factor for AS and atherothrombosis [31].

These observations revealed that AS pathogenesis is a complex process linked to dyslipidemia and associated inflammatory disorders and oxidative stress (Fig. 2).

Fig. 2
figure 2

Pathophysiology of atherosclerosis: Monocyte via very late antigen 4 (VLA4) binds vascular cell adhesion molecule 1 (VCAM-1) and enter the vascular lumen, then converted to macrophage which uptake cholesterol and converted to foam cells that undergo necrosis and deliver lipid into the lipid core with formation of atherosclerotic plaque

Full size image

Role of vinpocetine in atherosclerosis

Vinpocetine and inflammation

AS is regarded as an inflammatory disease, atherosclerotic plaque acts as a pathogen associated molecular pattern (PAMP) provokes immune response and infiltration of inflammatory cells [32]. Endothelial injury by ox-LDL promotes the expression of adhesion molecules like E and P selectin that increase recruitment of monocytes and the release of pro-inflammatory cytokines [32]. In addition, PAMP promotes the activation of NF-κB which is a master regulator of immune response, leading to the expression and release of pro-inflammatory cytokines [33]. Therefore, inhibition of NF-κB prevents the expression of adhesion molecules, release of pro-inflammatory cytokines and the development of inflammatory reactions in AS. Experimental studies illustrated that inhibition of NF-κB signaling pathway abrogates the development of AS in mice [34]. VPN has anti-inflammatory effect by inhibiting expression of NF-κB through stabilization inhibitor of IκBα [35]. Zhuang et al. showed that VPN inhibits AS progression in mice through suppression of NF-κB pathway. Importantly, ox-LDL activates NF-κB via stimulation of IKKα/β, IκBα, Akt and PI3K/Akt signaling pathway. VPN inhibits IKKα/β and IκBα preventing NF-κB activation and inflammatory reactions by targeting of IKKα/β is the main pathway for the anti-inflammatory effect of VPN [36]. Interestingly, VPN inhibits NF-κB–dependent inflammatory responses by directly targeting of IKK. VPN constrains intracellular IKK kinase activation and NF-κB–dependent transcriptional activity. VPN inhibits NF-κB–dependent inflammatory responses by directly targeting IKK, independent of its well-known action on PDE-1 activity and Ca2+ regulation [37].

Migration and transformation of monocytes to foam ells are mediated by NF-κB and monocyte chemoattractant protein 1 (MCP-1) which promotes the expression of scavenger receptor and differentiation of monocytes to foam cells [38]. Accumulation of ox-LDL in the monocytes triggers the differentiation of monocytes to macrophage and foam cells. MCP-1 increases the expression of CD36 which promote trans-endothelial migration of monocytes [39]. Different studies highlighted that NF-κB increases the expression of MCP-1 in various inflammatory disorders. Therefore, inhibition of NF-κB by VPN may reduce differentiation of monocytes to macrophage and foam cells.

Inflammation is a key factor at all stages of AS progression. Cells involved in pathogenesis of AS are activated by soluble factors and cytokines that influence the development of AS. Pro-inflammatory cytokines accelerate AS progression, while the anti-inflammatory cytokines ameliorate the pathogenesis of AS [40]. Certainly, cytokines are produced by and act (often synergistically) on almost all cells intricate in the pathogenesis of AS, contributing in all steps of the process, from the early endothelial dysfunction to the late formation and disruption of a vulnerable plaque [41]. Pro-atherogenic cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6 are secreted by macrophages, lymphocytes, natural killer cells, and vascular smooth muscle cells [42]. TNF-α and IL-1 signaling is mostly mediated by the p38 mitogen-activated protein kinase (p38MAPK)/NF-κΒ pathway which affects almost all cells involved in atherogenesis by promoting the expression of cytokines, adhesion molecules, and the migration and mitogenesis of vascular smooth muscle and endothelial cells [41]. Remarkably, most of pro-inflammatory cytokines released from macrophages are inhibited by action of VPN via NF-κB-dependent mechanism. VPN blocks monocyte adhesion and migration by inhibiting the expression and action of MCP-1 [43]. Though, VPN exhibits a selective inhibitory activity on the PDE-1 enzyme, though; the anti-inflammatory effect of VPN seems to be PDE-1-independent. VPN inhibits LPS-induced lung inflammation in mice by targeting NF-κB activation and, consequently, the production of NF-κB-related cytokines TNF-α and IL-1β, as well as the recruitment of polymorph nuclear cells [37]. VPN has anti-atherogenic effect through inhibition of NF-κB activation resulting in the inhibition the production of inflammatory cytokines like TNF-α and IL-6, and other inflammatory mediators in a PDE-1-independent manner [36]. In a model of endotoxemia, intraperitoneal administration of VPN reduced the expression of IL-1β and TNF-α in the hippocampus [44]. VPN has an analgesic activity in acetic acid-induced visceral nociception, validating the possible use of this compound in inflammatory pain conditions [45]. Nevertheless, it was not determined if similar analgesic and anti-inflammatory effects could be obtained by oral treatment with VPN in LPS-induced pain [45]. Besides, protective effect of VPN against ischemic reperfusion injury (IRI) could be attributed to inhibtion of NADPH oxidase/Nrf2, IKKβ/NF-κB p65, and cleaved caspase-3 expressions. Thus, VPN could improve oxidant/antioxidant balance, suppress inflammatory response, and promote cell survival after IRI [46]. These verdicts suggest that VPN may be effective against the development of inflammatory disorders in AS by suppressing of inflammatory reactions.

Vinpocetine and plaque stability

Most of acute cardiovascular events are due to thrombotic occlusion caused by ruptured atherosclerotic plaques. Plaque rupture is frequently caused by an inflammatory degradation of the plaque connective tissue, most importantly the fibrous cap [30]. Atherosclerotic plaques that are at high risk of rupturing are often referred to as vulnerable plaques. Such plaques are characterized by abundant inflammation, a large core of lipids and necrotic cells, and a thin fibrous cap. The plasma level of certain pro-inflammatory cytokines can be used as surrogate markers for the identification of patients with high-risk plaques [30]. Thus, abundant cytokines within the atherosclerotic plaques may diffuse into the circulation, and thereby; plasma levels of such cytokines could reflect the inflammatory activity in the plaques. Plasma levels of several cytokines have been shown to correlate with the progression of the AS or have been considered as markers of cardiovascular events [30].

It has been shown that macrophages within the atherosclerotic plaque are regarded as the major source of pro-inflammatory and inflammatory cytokines. Macrophage is considered as a key regulator of metabolic signals and inflammatory response in atherosclerotic plaque formation [47]. Therefore, macrophage activity and plaque contents are change in a dynamic balance. Macrophage lipid contents triggers inflammation and immune response by augmentation the sensitivity of TLR-4 to their ligands by inducing expression of nod-like receptor pyrin 3 (NLRP3) inflammasome [48]. Of note, the interaction of ox-LDL with monocytes/macrophages in the atherosclerotic plaque promotes inflammatory and oxidative stress disorders [47]. It has been shown that VPN attenuates the formation of atherosclerotic lesion in ApoE knockout mice. Besides, in vitro study illustrated that VPN blocks the uptake of ox-LDL in cultured macrophage through inhibition the expression of ox-LDL receptor [49]. VPN has weak inhibitory effect on the formation of foam cells, though it has strong inhibitory effect on ROS generation and the expression of pro-inflammatory cytokines in macrophages of atherosclerotic plaque as it attenuates the uptake of ox-LDL by foam cells [36].

Furthermore, VPN suppresses carotid intimal hyperplasia through inhibition the migration and proliferation of vascular smooth muscle cells (VSMCs) [50]. Wang et al. showed that VPN reduces the progression of carotid neo-intimal hyperplasia in diabetic rat following balloon injury [51]. Migration and proliferation of VSMCs are regulated by platelet derived growth factor (PDGF) which secreted from endothelial cells. PDGF promotes VSMCs phenotype shift during vascular injury by regulating autophagy [52]. Likewise, migration and proliferation of VSMCs are also augmented by Akt and extracellular signal regulated protein kinase 1/2 (ERK1/2) via activation of different signaling pathway [53]. In vitro study demonstrated that VPN blocks PDGF and ERK1/2-mediated VSMCs [50]. These observations suggest that VPN has a protective effect against intimae hyperplasia and vascular remodeling during development of AS.

Moreover, VPN stabilizes atherosclerotic plaque by increasing collagen content, plaque cap thickness and decreasing of lipid-rich core size through attenuation the expression of MMP-9 and TNF-α [36]. MMP-9 induces the degradation of plaque matrix causing plaque necrosis, rupture, and thrombosis. Inhibition of MMP-9 by the effect of VPN promotes plaque stability and prevents plaque-mediated complications. Thus, VPN may play a crucial role in preventing the development of atherosclerotic complication by enhancing of plaque stability.

Vinpocetine and PDE in atherosclerosis

It has been shown that PDE-1 A is highly expressed in foam cells of atherosclerotic plaque, while; PDE-1B and PDE-1 C are highly abundant in VSMCs. Different studies illustrated that PDE inhibitors by increasing cAMP/cGMP in VSMCs reduce intima media thickness and the progression of AS [54]. A prospective, randomized study involved 329 diabetic showed that cilotazol reduced intima media thickness compare to aspirin [55]. As well, sildenafil (PDE-5 inhibitor) improves endothelial dysfunction and vascular injury in mice [54]. VPN is a selective PDE-1 inhibitor increases cAMP/cGMP in VSMCs with subsequent inhibition of migration and differentiation. Intracellular cAMP is regulated by PDE and adenylyl cyclase that control atherogenesis through modulation the recruitment and migration of monocytes, and differentiation of macrophages to foam cells [56]. It has been shown that cAMP inhibits the release of pro-inflammatory cytokines from differentiated macrophage in the atherosclerotic plaque. Besides, cAMP attenuates the progression of atherosclerotic plaque by reducing macrophage cholesterol content via the expression of macrophage secretory pathway. In addition, increasing of cAMP is associated with inhibition the expression of MMP-9, platelet activation, thrombosis and atherogenesis [57]. Likewise, cGMP plays a critical role in maintaining of endothelial function through induction the expression and the release of NO. It has been observed that alteration of cGMP/NO signaling pathway is associated with atherogenesis and the development of AS. A previous experimental study demonstrated that chronic hypercholesterolemia-induced ROS reduce the availability of vasoprotective NO in rabbit, this effect was mediated by reducing of cGMP which intricate in intima proliferation and endothelial dysfunction through regulation of survival and phenotypic plasticity of VSMCs during vascular injury and the development of AS [58]. VSMCs express different types of cGMP effectors like cGMP-dependent protein kinase and NO-sensitive guanylyl cyclase that involved in the inhibition of VSMCs proliferation. Therefore, cGMP has a major role in regulating of atherogenesis by inhibiting VSMCs proliferation [59]. Thus, VPN by increasing of cAMP/cGMP could be effective in the management of AS through maintaining the endothelial integrity and inhibition of VSMCs proliferation [60].

Vinpocetine and oxidative stress in atherosclerosis and endothelial dysfunction

Oxidative stress is involved in the pathogenesis of various cardiovascular diseases including AS. AS represents a state of oxidative stress characterized by protein and lipid oxidations in the vascular endothelium [27]. Overproduction of ROS is an integral pathway in the development and progression of endothelial dysfunction and AS [61]. Oxidative stress-induced endothelial dysfunction is mediated by depletion of endothelium NO [62, 63]. It has been illustrated that oxidative stress promotes the formation of atherosclerotic plaque through induction the expression of adhesion molecules, inflammation and the development of endothelial dysfunction [64]. Endothelial NADPH oxidase is a master enzyme for generation of ROS that correlate with progression of endothelial dysfunction and AS [65]. Different studies revealed that LDL directly activates the endothelial NADPH oxidase through the expression of signal transduction like phospholipase A2 and release of arachidonic acid (AA) which involved in activation of NADPH oxidase [66, 67]. Monocytes, macrophages, VSMCs, and endothelial cells have ability to oxidized LDL through NADPH oxidase-dependent pathway [68]. Moreover, ROS are also produced by other enzymes and pathways including xanthin oxidase, mitochondrial eNOS and uncoupling eNOS [65]. The vascular endothelium is protected from the effect of oxidative stress by antioxidant enzyme system including catalase, superoxide dismutase, paraoxonase and glutathione peroxidase [69]. ROS induces atherogenesis by oxidative modification of phospholipids and lipoproteins. Therefore, oxidative/antioxidant imbalance promote macrophage polarization, formation of foam cells and formation of atherosclerotic plaque [20, 70].

VPN is regarded as an antioxidant agent reduces the propagation of oxidative stress by inhibiting the generation of ROS, inflammatory and oxidative stress disorders [5, 71]. In response to LPS, both macrophages and neutrophils through TLR4/NF-κB produce large amount of mediators including ROS and pro-inflammatory cytokines leading to inflammation and associated oxidative stress [71]. An experimental study revealed that administration of VPN 30 mg/kg inhibits LPS-induced oxidative stress in mice through inhibition of NF-κB signaling. Al-kuraishy et al. revealed that VPN attenuates gentamicin-induced acute kidney injury in rats by inhibiting the development and progression of oxidative stress [5]. Recently, VPN-induced inhibition of PDE1 prevents brain oxidative stress in behavioral phenotype of autism spectrum disorders [72]. As well, VPN mitigates the inflammatory and oxidative stress disorders in Covid-19 which linked with hyperinflammation and oxidative stress [3]. These findings proposed that VPN could be effective in reducing of oxidative stress a cornerstone in the pathogenesis of AS through inhibition of NF-κB and PDE1.

Furthermore, hemodynamic shear stress is a frictional force on the vascular endothelium controls endothelium homeostasis in normal physiological process [73]. The laminar shear stress prevents endothelial injury and the development of AS, whereas; disturbed blood flow induces the development of atherothrmbosis [74]. It has been reported that disturbed blood flow due to endothelial dysfunction in AS induce activation of endothelial voltage-gated Na+ 2 channel which promote expression of ERK1/2 and NF-κB activation [75]. Of note, VPN is regarded as a potent inhibitor of voltage-gated Na+ 2 channel preventing cell toxicity and death through mitigation of ERK1/2 and NF-κB activation [8]. Taken together, VPN through mitigation of inflammatory and oxidative stress, and plaque stability effects could be effective agent in the management of AS (Fig. 3).

Fig. 3
figure 3

Role of vinpocetine in atherosclerosis: Vinpocetine inhibits NF-κB and related signaling leading suppression release of pro-inflammatory cytokines, reactive oxygen species (ROS), proliferation, and migration of vascular smooth muscle cells

Full size image

Conclusion

VPN is a potent inhibitor of PDE-1 that has anti-inflammatory and antioxidant effects through inhibition the expression of NF-κB. VPN has been shown to be effective against the development and progression of AS. Most of pro-inflammatory cytokines released from macrophages are inhibited by action of VPN through NF-κB-dependent mechanism. VPN prevents NF-κB activation and inflammatory reactions. Besides, VPN blocks monocyte adhesion and migration by inhibiting the expression of pro-inflammatory cytokines. VPN may reduce the differentiation of monocytes to macrophage and foam cells. Remarkably, most of pro-inflammatory cytokines released from macrophages are inhibited by action of VPN via NF-κB-dependent mechanism .VPN blocks monocyte adhesion and migration by inhibiting the expression and action of MCP-1. In addition, VPN may play a crucial role in preventing development of atherosclerotic complication through enhancement of plaque stability. VPN by increasing of cAMP/cGMP could be effective in the management of AS by maintaining endothelial integrity and inhibition of VSMCs proliferation. VPN is effective in reducing of oxidative stress a cornerstone in the pathogenesis of AS through inhibition of NF-κB and PDE1. Taken together, VPN promotes plaque stability and prevents erosion and rupture of atherosclerotic plaque. In conclusion, VPN through mitigation of inflammatory and oxidative stress with plaque stability effects could be effective agent in the management of AS. This review cannot gives the final conclusion regarding the atheroprotective role of VPN in AS. Herein, preclinical and clinical studies are reasonable in this regard.

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. Ferreira M-JU. Natural products in drug discovery and human health. Phytochem Rev. 2021;20(1):1–4.

    Article  CAS  Google Scholar 

  2. Al-Kuraishy HM, Al-Gareeb AI, Naji MT, Al-Mamorry F. Role of vinpocetine in ischemic stroke and poststroke outcomes: a critical review. Brain Circulation. 2020;6(1):1.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Al-Kuraishy HM, Al-Gareeb AI, Fageyinbo MS, Batiha GE-S. Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19. Future Sci OA. 2022(0):FSO797.

  4. Al-kuraishy HM, Al-Gareeb AI. Vinpocetine and ischemic stroke. Ischemic Stroke. 2020;27.

  5. Al-Kuraishy HM, Al-Gareeb AI, Al-Nami MS. Vinpocetine improves oxidative stress and pro-inflammatory mediators in acute kidney injury. Int J Prev Med. 2019;10.

  6. Zhang Y-s, Li J-d, Yan C. An update on vinpocetine: new discoveries and clinical implications. Eur J Pharmacol. 2018;819:30–4.

    Article  CAS  PubMed  Google Scholar 

  7. Zhang L, Yang L. Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature. Molecules. 2014;20(1):335–47.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bönöczk P, Gulyás B, Adam-Vizi V, Nemes A, Kárpáti E, Kiss B, et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000;53(3):245–54.

    Article  PubMed  Google Scholar 

  9. Ansari MA, Iqubal A, Ekbbal R, Haque SE. Effects of Nimodipine, vinpocetine and their combination on isoproterenol-induced myocardial infarction in rats. Biomed Pharmacother. 2019;109:1372–80.

    Article  CAS  PubMed  Google Scholar 

  10. Wu M-p, Zhang Y, Xu X, Zhou Q, Li J-D, Yan C. Vinpocetine attenuates pathological cardiac remodeling by inhibiting Cardiac Hypertrophy and Fibrosis. Cardiovasc Drugs Ther. 2017;31.

  11. Medina AE. Vinpocetine as a potent antiinflammatory agent. Proceedings of the National Academy of Sciences. 2010;107(22):9921-2.

  12. Ping Z, Xiaomu W, Xufang X, Liang S. Vinpocetine regulates levels of circulating TLRs in Parkinson’s disease patients. Neurol Sci. 2019;40(1):113–20.

    Article  PubMed  Google Scholar 

  13. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–33.

    Article  CAS  PubMed  Google Scholar 

  14. Fok P-W, Lanzer P. Media sclerosis drives and localizes atherosclerosis in peripheral arteries. PLoS ONE. 2018;13(10):e0205599.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Schipper HS, de Ferranti S. Atherosclerotic cardiovascular risk as an emerging priority in pediatrics. Pediatrics. 2022;150(5).

  16. Vergallo R, Crea F. Atherosclerotic plaque healing. N Engl J Med. 2020;383(9):846–57.

    Article  CAS  PubMed  Google Scholar 

  17. Shi P, Ji H, Zhang H, Yang J, Guo R, Wang J. circANRIL reduces vascular endothelial injury, oxidative stress and inflammation in rats with coronary atherosclerosis. Experimental Therapeutic Med. 2020;20(3):2245–51.

    CAS  Google Scholar 

  18. Rasheed A, Shawky SA, Tsai R, Jung RG, Simard T, Saikali MF, et al. The secretome of liver X receptor agonist-treated early outgrowth cells decreases atherosclerosis in Ldlr-/- mice. Stem Cells Transl Med. 2021;10(3):479–91.

    Article  CAS  PubMed  Google Scholar 

  19. Al-Maiahy T, Al-Gareeb A, Al-Kuraishy H. Role of dyslipidemia in the development of early-onset preeclampsia. J Adv Pharm Tech Res. 2021;12(1):73–8.

    Article  Google Scholar 

  20. Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxidative medicine and cellular longevity. 2020;2020.

  21. Chiorescu RM, Mocan M, Inceu AI, Buda AP, Blendea D, Vlaicu SI. Vulnerable atherosclerotic plaque: is there a molecular signature? Int J Mol Sci. 2022;23(21):13638.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kadhim S, Al-Windy S, Al-Kuraishy H, Al-Gareeb A. Endothelin-1 is a surrogate biomarker link severe periodontitis and endothelial dysfunction in hypertensive patients: the potential nexus. J Int Oral Health. 2019;11(6):369–75.

    Article  Google Scholar 

  23. Al-kuraishy HM, Hussien NR, Al-Niemi MS, Fahad EH, Al-Buhadily AK, Al-Gareeb AI, et al. SARS-CoV-2 induced HDL dysfunction may affect the host’s response to and recovery from COVID-19. Immun Inflamm Dis. 2023;11(5):e861.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Al-kuraishy H. Fenofibrate and Crataegus oxyacantha is an Effectual Combo for Mixed Dyslipidemia2020.

  25. Gill PK, Dron JS, Hegele RA. Genetics of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol. 2021;36(3):264–71.

    Article  PubMed  Google Scholar 

  26. Jinnouchi H, Guo L, Sakamoto A, Torii S, Sato Y, Cornelissen A, et al. Diversity of macrophage phenotypes and responses in atherosclerosis. Cell Mol Life Sci. 2020;77(10):1919–32.

    Article  CAS  PubMed  Google Scholar 

  27. Poznyak AV, Grechko AV, Orekhova VA, Chegodaev YS, Wu W-K, Orekhov AN. Oxidative stress and antioxidants in atherosclerosis development and treatment. Biology. 2020;9(3):60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lee YW, Kim PH, Lee WH, Hirani AA. Interleukin-4, oxidative stress, vascular inflammation and atherosclerosis. Biomol Ther (Seoul). 2010;18(2):135–44.

    Article  CAS  PubMed  Google Scholar 

  29. Ho F, Watson A, Elbatreek MH, Kleikers PW, Khan W, Sourris KC, et al. Endothelial reactive oxygen-forming NADPH oxidase 5 is a possible player in diabetic aortic aneurysm but not atherosclerosis. Sci Rep. 2022;12(1):1–10.

    Article  Google Scholar 

  30. Wang C, Wang H, Zhao Z, Xiao S, Zhao Y, Duan C, et al. Pediococcus acidilactici AS185 attenuates early atherosclerosis development through inhibition of lipid regulation and inflammation in rats. J Funct Foods. 2019;60:103424.

    Article  CAS  Google Scholar 

  31. He D, Zhao M, Wu C, Zhang W, Niu C, Yu B, et al. Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1. Redox Biol. 2018;15:228–42.

    Article  CAS  PubMed  Google Scholar 

  32. Ou HC, Chou WC, Hung CH, Chu PM, Hsieh PL, Chan SH, et al. Galectin-3 aggravates ox‐LDL‐induced endothelial dysfunction through LOX‐1 mediated signaling pathway. Environ Toxicol. 2019;34(7):825–35.

    Article  CAS  PubMed  Google Scholar 

  33. Wu G, Zhu Q, Zeng J, Gu X, Miao Y, Xu W, et al. Extracellular mitochondrial DNA promote NLRP3 inflammasome activation and induce acute lung injury through TLR9 and NF-κB. J Thorac Disease. 2019;11(11):4816.

    Article  Google Scholar 

  34. Mallavia B, Recio C, Oguiza A, Ortiz-Muñoz G, Lazaro I, Lopez-Parra V, et al. Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis. Am J Pathol. 2013;182(5):1910–21.

    Article  CAS  PubMed  Google Scholar 

  35. Wang H, Zhang K, Zhao L, Tang J, Gao L, Wei Z. Anti-inflammatory effects of vinpocetine on the functional expression of nuclear factor-kappa B and tumor necrosis factor-alpha in a rat model of cerebral ischemia–reperfusion injury. Neurosci Lett. 2014;566:247–51.

    Article  CAS  PubMed  Google Scholar 

  36. Zhuang J, Peng W, Li H, Lu Y, Wang K, Fan F, et al. Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/-mice. PLoS ONE. 2013;8(12):e82509.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, et al. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A. 2010;107(21):9795–800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Tabata T, Mine S, Kawahara C, Okada Y, Tanaka Y. Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochem Biophys Res Commun. 2003;305(2):380–5.

    Article  CAS  PubMed  Google Scholar 

  39. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets-Inflammation Allergy. 2005;4(3):281–6.

    Article  CAS  Google Scholar 

  40. Fatkhullina AR, Peshkova IO, Koltsova EK. The role of cytokines in the development of atherosclerosis. Biochem (Mosc). 2016;81(11):1358–70.

    Article  CAS  Google Scholar 

  41. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016;37(22):1723–32.

    Article  CAS  PubMed  Google Scholar 

  42. Alkazmi L, Al-kuraishy H, Al-Gareeb A, Alexiou A, Papadakis M, Saad HM et al. The potential role of scavenger receptor B type I (SR-BI) in SARS‐CoV‐2 infection. Immunity, Inflammation and Disease. 2023;11.

  43. Akhter N, Wilson A, Thomas R, Al-Rashed F, Kochumon S, Al-Roub A, et al. Ros/tnf-α crosstalk triggers the expression of il-8 and mcp-1 in human monocytic thp-1 cells via the nf-κb and erk1/2 mediated signaling. Int J Mol Sci. 2021;22(19):10519.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Gómez CD, Buijs RM, Sitges M. The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus. J Neurochem. 2014;130(6):770–9.

    Article  PubMed  Google Scholar 

  45. Abdel Salam OM. Vinpocetine and piracetam exert antinociceptive effect in visceral pain model in mice. Pharmacol Rep. 2006;58(5):680–91.

    CAS  PubMed  Google Scholar 

  46. Azouz AA, Hersi F, Ali FEM, Hussein Elkelawy AMM, Omar HA. Renoprotective effect of vinpocetine against ischemia/reperfusion injury: modulation of NADPH oxidase/Nrf2, IKKβ/NF-κB p65, and cleaved caspase-3 expressions. J Biochem Mol Toxicol. 2022;36(7):e23046.

    Article  CAS  PubMed  Google Scholar 

  47. Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019;20:247–60.

    Article  CAS  PubMed  Google Scholar 

  48. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Cai Y, Li J-D, Yan C. Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun. 2013;434(3):439–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Cai Y, Knight WE, Guo S, Li J-D, Knight PA, Yan C. Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. J Pharmacol Exp Ther. 2012;343(2):479–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wang K, Wen L, Peng W, Li H, Zhuang J, Lu Y, et al. Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury. PLoS ONE. 2014;9(5):e96894.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Han J-H, Park H-S, Lee D-H, Jo J-H, Heo K-S, Myung C-S. Regulation of autophagy by controlling Erk1/2 and mTOR for platelet-derived growth factor-BB-mediated vascular smooth muscle cell phenotype shift. Life Sci. 2021;267:118978.

    Article  CAS  PubMed  Google Scholar 

  53. Yu S, Chen Y, Chen S, Ye N, Li Y, Sun Y. Klotho inhibits proliferation and migration of angiotensin II-induced vascular smooth muscle cells (VSMCs) by modulating NF-κB p65, akt, and extracellular signal regulated kinase (ERK) signaling activities. Med Sci Monitor: Int Med J Experimental Clin Res. 2018;24:4851.

    Article  CAS  Google Scholar 

  54. Priksz D, Bombicz M, Varga B, Kurucz A, Gesztelyi R, Balla J, et al. Upregulation of myocardial and vascular phosphodiesterase 9A in a model of atherosclerotic cardiovascular disease. Int J Mol Sci. 2018;19(10):2882.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Katakami N, Kim Y-S, Kawamori R, Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation. 2010;121(23):2584–91.

    Article  CAS  PubMed  Google Scholar 

  56. Fantidis P. The role of intracellular 3’5’-cyclic adenosine monophosphate (cAMP) in atherosclerosis. Curr Vasc Pharmacol. 2010;8(4):464–72.

    Article  CAS  PubMed  Google Scholar 

  57. Zhou Y, Cao ZQ, Wang HY, Cheng YN, Yu LG, Zhang XK, et al. The anti-inflammatory effects of Morin hydrate in atherosclerosis is associated with autophagy induction through cAMP signaling. Mol Nutr Food Res. 2017;61(9):1600966.

    Article  Google Scholar 

  58. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proceedings of the National Academy of Sciences. 2004;101(47):16671-6.

  59. Lehners M, Dobrowinski H, Feil S, Feil R. cGMP signaling and vascular smooth muscle cell plasticity. J Cardiovasc Dev Disease. 2018;5(2):20.

    Article  Google Scholar 

  60. Zhang C, Yan C. Updates of recent vinpocetine research in treating cardiovascular diseases. J Cell Immunol. 2020;2(5):211.

    PubMed  PubMed Central  Google Scholar 

  61. Jacinto TA, Meireles GS, Dias AT, Aires R, Porto ML, Gava AL, et al. Increased ROS production and DNA damage in monocytes are biomarkers of aging and atherosclerosis. Biol Res. 2018;51(1):1–13.

    Article  Google Scholar 

  62. Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ. Concept and connotation of oxidative stress in preeclampsia. J Lab Physicians. 2018;10(03):276–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Al-Kuraishy HM, Al-Gareeb AI, Al-Nami MS. Irbesartan attenuates gentamicin-induced nephrotoxicity in rats through modulation of oxidative stress and endogenous antioxidant capacity. Int J Prev Med. 2020;11:16.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxidative medicine and cellular longevity. 2019;2019.

  65. Poznyak AV, Grechko AV, Orekhova VA, Khotina V, Ivanova EA, Orekhov AN. NADPH oxidases and their role in atherosclerosis. Biomedicines. 2020;8(7):206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Hussien NR, Al-Niemi MS, Al-Kuraishy HM, Al-Gareeb AI. Statins and Covid-19: the neglected front of bidirectional effects. J Pak Med Assoc. 2021;71(Suppl 8):S133–6.

    Google Scholar 

  67. Manea S-A, Vlad M-L, Fenyo IM, Lazar A-G, Raicu M, Muresian H, et al. Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis. Redox Biol. 2020;28:101338.

    Article  CAS  PubMed  Google Scholar 

  68. Lixia G, Haiyun Z, Xia Z. The clinical effects of resveratrol on atherosclerosis treatment and its effect on the expression of NADPH oxidase complex genes in vascular smooth muscle cell line. Cell Mol Biol. 2021;67(3):148–52.

    Article  PubMed  Google Scholar 

  69. Al-Thomali AW, Al-Kuraishy HM, Al-Gareeb AI, Al-buhadiliy K, De Waard A, Sabatier M. Role of neuropilin 1 in COVID-19 patients with acute ischemic stroke. Biomedicines. 2022;10(8):2032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. ali b, Al-kuraishy H, Al-Gareeb A, Al-Hamash S, Waard M et al. Sabatier j-m,. Montelukast and Acute Coronary Syndrome: The Endowed Drug. Pharmaceuticals. 2022;15.

  71. Ruiz-Miyazawa KW, Pinho-Ribeiro FA, Zarpelon AC, Staurengo-Ferrari L, Silva RL, Alves-Filho JC, et al. Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB. Chemico-Biol Interact. 2015;237:9–17.

    Article  CAS  Google Scholar 

  72. Luhach K, Kulkarni GT, Singh VP, Sharma B. Vinpocetine amended prenatal valproic acid induced features of ASD possibly by altering markers of neuronal function, inflammation, and oxidative stress. Autism Res. 2021;14(11):2270–86.

    Article  PubMed  Google Scholar 

  73. Al-kuraishy H, Al-Gareeb A, Albuhadilly A. Vinpocetine and Pyritinol: a New Model for Blood Rheological Modulation in Cerebrovascular Disorders-A Randomized Controlled Clinical Study. Biomed Res Int. 2014;2014:324307.

    Google Scholar 

  74. Huynh DTN, Heo K-S. Therapeutic targets for endothelial dysfunction in vascular diseases. Arch Pharm Res. 2019;42(10):848–61.

    Article  CAS  PubMed  Google Scholar 

  75. Gilbert G, Courtois A, Dubois M, Cussac L-A, Ducret T, Lory P, et al. T-type voltage gated calcium channels are involved in endothelium-dependent relaxation of mice pulmonary artery. Biochem Pharmacol. 2017;138:61–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through large group Research Project under grant number RGP2/486/44.

Funding

Open Access funding enabled and organized by Projekt DEAL. This work was supported by the University of Witten-Herdecke Germany.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, College of Pharmacy, Taif University, Al Huwaya, Taif, Saudi Arabia

    Abdullah A. Alshehri & Wael Y. Khawagi

  2. Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq

    Hayder M. Al-kuraishy

  3. Jabir ibn Hayyan Medical University, PO.Box13, Al-Ameer Qu./Najaf, Iraq

    Ali I. Al-Gareeb

  4. Department of Pharmacy, Al-Mustaqbal University College, Hillah, Babylon, 51001, Iraq

    Sabrean F. Jawad

  5. Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, NSW, 2770, Australia

    Athanasios Alexiou

  6. AFNP Med, Wien, 1030, Austria

    Athanasios Alexiou

  7. Department of Surgery II, University Hospital Witten-Herdecke, Universityof Witten-Herdecke, Heusnerstrasse 40, 42283, Wuppertal, Germany

    Marios Papadakis

  8. Department of Clinical Pharmacy, College of Pharmacy, King Khalid University Abha, Abha, Saudi Arabia

    Abdullah A Assiri

  9. Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, Egypt

    Heba Elhadad

  10. Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, 22511, Egypt

    Gaber El-Saber Batiha

  11. University Centre for Research & Development, Chandigarh University, Chandigarh-Ludhiana Highway, Mohali, Punjab, India

    Athanasios Alexiou

  12. Department of Research & Development, Funogen, Athens, 11741, Greece

    Athanasios Alexiou

Authors
  1. Abdullah A. Alshehri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hayder M. Al-kuraishy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali I. Al-Gareeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabrean F. Jawad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wael Y. Khawagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Athanasios Alexiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marios Papadakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Abdullah A Assiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Heba Elhadad
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gaber El-Saber Batiha
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.A.A, H.M.A, A.I.A, S.F.J, W.Y.K., A.A, M.P, A.A.A, H.E, G.E.B drafted the manuscript, and H.M.A, A.I.A drew the figures. All authors contributed to the editing of the manuscript, performed extensive proofreading of the manuscript. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Marios Papadakis.

Ethics declarations

Ethical approval

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alshehri, A.A., Al-kuraishy, H.M., Al-Gareeb, A.I. et al. The anti-inflammatory properties of vinpocetine mediates its therapeutic potential in management of atherosclerosis. J Inflamm 21, 19 (2024). https://doi.org/10.1186/s12950-024-00394-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12950-024-00394-x

Keywords

Journal of Inflammation

ISSN: 1476-9255

Contact us